• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novocure touts data from Optune-paclitaxel combination study

September 2, 2016 By drugdelivery

NovoCureBy Sarah Faulkner

NovoCure (NSDQ:NVCR) announced yesterday that its ‘tumor treating fields, combined with the drug paclitaxel, are effective against ovarian cancer, the 5th most-common cause of cancer death in women in the US.

The St. Helier, N.J.-based company won FDA approval in July for the Optune device to treat a type of brain cancer called glioblastoma.

TTFields are low intensity, alternating electric fields designed to disrupt the division process in cancerous cells. The device is portable, designed for continuous, home use.

The company’s preclinical research into ovarian cancer, published in the International Journal of Cancer, showed positive results in vitro and in vivo. The study examined the effects of TTFields and paclitaxel, a drug used to treat ovarian, lung, pancreatic, and other cancers. Paclitaxel is also used with some drug-eluting stents to inhibit restenosis.

In both in vivo and in vitro studies, combining TTFields and paclitaxel significantly reduced the cancer cell count, more than either therapy alone. Results from a simulation testing the distribution of the electric fields into the abdomen showed that the device could successfully distribute electric fields to the proper depth in order to reach the ovaries.

“Treatment with TTFields is broadly applicable and has shown a consistent anti-mitotic effect in our preclinical and clinical research over the last 16 years,” chief science officer Eilon Kirson said in prepared remarks. “Novocure is committed to increasing the understanding of the mechanisms of action and potential clinical utility of TTFields in multiple solid tumors through the presentation and peer-reviewed publication of high quality data.”

In light of the preclinical results, Novocure kicked off an open-label, Phase II pilot study of TTFields in combination with paclitaxel to treat recurrent ovarian cancer. The Innovate trial is fully enrolled and Novocure expects to share preliminary results in December of 2016.

Filed Under: Clinical Trials, Drug-Device Combinations, Oncology Tagged With: NovoCure

IN CASE YOU MISSED IT

  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Senseonics beats The Street in Q1 following Eversense E3 launch

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS